This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baim, D. S. Articles by Frederick, M. M. Search for Related Content PubMed PubMed Citation Articles by Baim, D. S. Articles by Frederick, M. M. Pubmed/NCBI databases Medline Plus Health Information Angioplasty Heart Attack

Circulation, Vol 85, 93-105, Copyright © 1992 by American Heart Association

ARTICLES

Coronary angioplasty performed within the thrombolysis in Myocardial Infarction II study

DS Baim, DJ Diver, F Feit, MA Greenberg, DR Holmes, BH Weiner, DO Williams, MJ Schweiger, BG Brown and MM Frederick
Cardiovascular Division, Beth Israel Hospital, Boston, MA 02215.

BACKGROUND. Percutaneous transluminal coronary angioplasty (PTCA) of the infarct-related artery was performed within 42 days of recombinant tissue-type plasminogen activator (rt-PA) administration in 1,414 of the 3,534 patients who participated in the Thrombolysis In Myocardial Infarction (TIMI) II study. Primary angiographic success was obtained in 88.7%, with bypass surgery within 24 hours in 3.3% and death within 24 hours in 0.7% of patients. By 1 year, 25.1% of the 1,414 patients had sustained one or more adverse outcomes including death (3.6%), reinfarction (8.4%), or the need for further revascularization (20%). METHODS AND RESULTS. Despite these generally favorable results, multivariate testing identified several anatomic and clinical subgroups as having an increased risk ratio (RR) for adverse outcome: Unsuccessful PTCA was more common in patients undergoing protocol- assigned PTCA within 2 hours of rt-PA administration (RR, 2.7; p less than 0.001) and in patients over age 70 years (RR, 1.7; p = 0.034). The need for further revascularization within 1 year was increased in the 30.4% of patients with multivessel disease (RR, 2.5; p less than 0.001), patients with prior angina (RR, 1.4; p less than 0.006), or those undergoing ischemia-driven PTCA within 15 hours of rt-PA administration (RR, 1.7; p = 0.022). The risk of death or recurrent infarction within 1 year was increased by the presence of multivessel disease (RR, 1.6; p = 0.007) or prior angina (RR, 1.5; p = 0.014). CONCLUSIONS. These observations do not necessarily apply to patients undergoing primary PTCA (or PTCA after other thrombolytic agents); however, they do offer a unique yardstick against which to evaluate the results of PTCA in myocardial infarction.

This article has been cited by other articles:

				C. Bauters, P. Khanoyan, E. P. Mc Fadden, P. Quandalle, J.-M. Lablanche, and M. E. Bertrand Restenosis After Delayed Coronary Angioplasty of the Culprit Vessel in Patients With a Recent Myocardial Infarction Treated by Thrombolysis Circulation, March 1, 1995; 91(5): 1410 - 1418. [Abstract] [Full Text]